Surgical Downstaging in an Open-Label Phase II Trial of Denosumab in Patients with Giant Cell Tumor of Bone

被引：0
作者：
Piotr Rutkowski
Stefano Ferrari
Robert J. Grimer
Paul D. Stalley
Sander P. D. Dijkstra
Andrzej Pienkowski
Gualter Vaz
Jay S. Wunder
Leanne L. Seeger
Amy Feng
Zachary J. Roberts
Bruce A. Bach
机构：
[1] Maria Sklodowska-Curie Memorial Center and Institute of Oncology,Department of Soft Tissue/Bone Sarcoma and Melanoma
[2] Istituto Ortopedico Rizzoli,Chemotherapy Unit
[3] Royal Orthopaedic Hospital,Orthopaedic Oncology Unit
[4] Royal Prince Alfred Hospital,Department of Orthopaedic Surgery
[5] Leiden University Medical Center,Department of Orthopedic Surgery
[6] Centre Leon Berard,Department of Surgery
[7] Mount Sinai Hospital,Samuel Lunenfeld Research Institute
[8] University of Toronto,Department of Radiology
[9] David Geffen School of Medicine at University of California Los Angeles,Global Biostatistical Science
[10] Amgen Inc.,Global Development Oncology Therapeutics
[11] Amgen Inc.,undefined
来源：
Annals of Surgical Oncology | 2015年 / 22卷
关键词：
Denosumab; Bloc Resection; Electronic Supplementary Table; Denosumab Treatment; Intralesional Curettage;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2860 / 2868
页数：8
相关论文
共 50 条
  • [1] Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab
    Palmerini, Emanuela
    Seeger, Leanne L.
    Gambarotti, Marco
    Righi, Alberto
    Reichardt, Peter
    Bukata, Susan
    Blay, Jean-Yves
    Dai, Tian
    Jandial, Danielle
    Picci, Piero
    BMC CANCER, 2021, 21 (01)
  • [2] Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab
    Emanuela Palmerini
    Leanne L. Seeger
    Marco Gambarotti
    Alberto Righi
    Peter Reichardt
    Susan Bukata
    Jean-Yves Blay
    Tian Dai
    Danielle Jandial
    Piero Picci
    BMC Cancer, 21
  • [3] Denosumab in Giant Cell Rich Tumors of Bone: An Open-Label Multicenter Phase II Study
    Lipplaa, Astrid
    Schreuder, Willem H.
    Pichardo, Sarina E. C.
    Gelderblom, Hans
    ONCOLOGIST, 2023, : E1005 - E1104
  • [4] Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial
    Ueda, T.
    Morioka, H.
    Nishida, Y.
    Kakunaga, S.
    Tsuchiya, H.
    Matsumoto, Y.
    Asami, Y.
    Inoue, T.
    Yoneda, T.
    ANNALS OF ONCOLOGY, 2015, 26 (10) : 2149 - 2154
  • [5] RANKL, denosumab, and giant cell tumor of bone
    Thomas, David M.
    CURRENT OPINION IN ONCOLOGY, 2012, 24 (04) : 397 - 403
  • [6] Denosumab for the treatment of giant cell tumor of the bone
    Brodowicz, Thomas
    Hemetsberger, Margit
    Windhager, Reinhard
    FUTURE ONCOLOGY, 2015, 11 (13) : 1881 - 1894
  • [7] Denosumab for treating giant cell tumor of bone
    Jagiello-Wieczorek, Ewelina
    Pienkowski, Andrzej
    Rutkowski, Piotr
    EXPERT OPINION ON ORPHAN DRUGS, 2015, 3 (10): : 1219 - 1229
  • [8] A recurrent giant cell tumor of bone treated with denosumab
    Stadler, Nicola
    Fingernagel, Thomas
    Hofstaetter, Stefan G.
    Trieb, Klemens
    CLINICS AND PRACTICE, 2015, 5 (01)
  • [9] The Role of Denosumab for Surgical Outcomes in Patients with Giant Cell Tumour of Bone: A Systematic Review
    Gupta, Abha
    Durocher-Allen, Lisa
    Popovic, Snezana
    Tozer, Richard
    Yao, Xiaomei
    Ghert, Michelle
    CURRENT ONCOLOGY, 2021, 28 (02) : 1302 - 1313
  • [10] Role of (Neo)adjuvant Denosumab for Giant Cell Tumor of Bone
    Palmerini, Emanuela
    Staals, Eric Lodewijk
    Jones, Louis Baxter
    Donati, Davide Maria
    Longhi, Alessandra
    Randall, R. Lor
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2020, 21 (08)
12345